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Abstract
Objective: Cholinergic vasodilation has been thought to play little if any role in the regulation of blood pressure in humans. Autonomic
denervation potentiates the vasoconstriction evoked by nitric oxide synthase inhibition in humans, but the mechanism is unclear. We
hypothesized that this may be related to loss of neuronal, non-nitric-oxide-dependent vasodilation. Methods: To test this hypothesis, we
examined effects of cholinergic blockade on blood pressure, heart rate and peripheral vascular responses to systemic infusion of the
nitric-oxide-dependent vasoconstrictor L-NMMA (0.5 mg/kg/min over 15 min) in eight normal subjects. Results: The L-NMMA-induced
increase in mean (6S.E.) arterial pressure was roughly three times larger (P50.002) in the presence than in the absence of cholinergic
blockade (3866 vs. 1362 mmHg). Similarly, the increase in systemic and calf vascular resistance was more than twofold larger during
L-NMMA–atropine. This potentiation was specific for nitric-oxide-dependent vasoconstriction, because atropine did not alter the
responses to phenylephrine infusion. Cholinergic blockade also altered (P50.004) the heart rate response to nitric oxide synthase
inhibition; during L-NMMA alone heart rate decreased by 1062 beats /min, whereas during L-NMMA–atropine infusion it increased by
1464 beats /min. Conclusion: Cholinergic mechanisms play an important hitherto unrecognized role in offsetting the hypertension and
cardiac sympathetic activation caused by nitric oxide synthase inhibition in humans. Decreased parasympathetic activity and impaired
nitric oxide synthesis characterize several cardiovascular disease states, as well as normal aging. The conjunction of these two defects
could trigger sudden death and contribute to the hypertension of the elderly. Ó 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction L-arginine by the ubiquitous enzyme nitric oxide synthase
(NOS) [6], regulates vascular tone by a direct action at the
The vascular endothelium and the autonomic nervous vasculature [7], by modulating central neural vasoconstric-
system interact between each other and play a key role in tor outflow [7–13], and via its release from sympathetic
the regulation of the cardiovascular system [1,2]. Major nitrergic vasodilator nerves [14]. While the importance of
cardiovascular disease states such as hypertension, heart parasympathetic control of heart rate (HR) is well estab-
failure and myocardial infarction are associated with lished [15], little is known regarding the role of cholinergic
endothelial [3,4] and autonomic dysfunction [5], as is vasodilator mechanisms in the regulation of blood pressure
aging, another risk factor for cardiovascular disease. Nitric in humans [16], and the possibility of an interaction
oxide (NO) which is synthesized from the amino acid between the cholinergic and the NO–L-arginine system.
Autonomic denervation potentiates the vasoconstrictor
G
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nism is not known [17]. We hypothesized that cholinergic
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mechanisms attenuate the vasoconstrictor effects of NOS 2.5. Drugs
inhibition in humans. To test this hypothesis, we examined
the effects of cholinergic blockade on the pressor response Drugs were dissolved in physiological saline immedi-
to systemic infusion of the NO-dependent vasoconstrictor ately before use. L-NMMA, L- and D-Arginine were
¨L-NMMA, and compared this response with the one obtained from Clinalfa (Laufelfingen, Switzerland), at-
evoked by the non-NO-dependent vasoconstrictor phenyl- ropine from Syntetica (Mendrisio, Switzerland), phenyl-
ephrine. ephrine from Winthrop (Zurich, Switzerland) and propran-
olol from Zeneca (Luzern, Switzerland).
2.6. Experimental protocols2. Methods
2.6.1. Protocol 1: cardiovascular effects of L-NMMA2.1. Subjects
infusion alone
After instrumentation the subject rested quietly for 30Eight healthy subjects [three women and five men, mean
min. The subject then received sequential infusions of(6S.D.) weight 6763 kg, height 17563 cm, body mass
2 normal saline (1 ml /min for 20 min), L-NMMA (0.5index 21.960.5 kg/m , age 2562 years] participated in
mg/kg/min for 15 min), D-arginine (100 mg/kg over 10this study after providing informed written consent. All
min, n55) and L-arginine (100 mg/kg over 10 min).subjects were normotensive, were taking no medications,
Hemodynamic measurements were recorded during twoand had no evidence of metabolic or cardiovascular
5-min periods of the saline infusion and during the last 5disease. The studies were performed in the morning after
min of each drug infusion. In four of the subjects we alsoan overnight fast. The subjects were asked to abstain from
measured cardiac output (echocardiography). The presentalcohol, caffeine and tobacco for at least 24 h before each
dose of L-NMMA was chosen, because it was found tostudy. The experimental protocol was approved by the
consistently increase calf vascular resistance [9]. L-Ar-Institutional Review Board on Human Investigation and
ginine at the dose used in these studies was found tothe investigation conforms with the principles outlined in
consistently reverse the hemodynamic effect of L-NMMAthe Declaration of Helsinki.
[9].
2.2. General procedures 2.6.2. Protocol 2: cardiovascular effects of L-NMMA
infusion during cholinergic blockadeThe subjects were studied in the supine position. Heart After instrumentation the subject rested quietly for 30
rate (electrocardiogram) and blood pressure (Finapres)
min. After resting control values had been measured, a
were measured continuously. For drug infusion, an in- 2 2prime (0.4 mg/m over 10 min) continuous (0.3 mg/m /
travenous catheter was inserted in an antecubital vein. h) atropine infusion was started. 30 min after its start,
sequential infusions of L-NMMA (0.5 mg/kg/min for 15
2.3. Measurement of calf blood flow min), D-arginine (100 mg/kg over 10 min, n55) and
L-arginine (100 mg/kg over 10 min) were superimposed
Calf blood flow was measured by venous occlusion on the atropine infusion. Hemodynamic measurements
plethysmography, using mercury-in-Silastic strain gauges. were recorded during two 5-min periods of baseline and
The calf was elevated 10–15 cm above the level of the atropine infusion, and during the last 5 min of the L-
right atrium to collapse the veins. The circulation to the NMMA infusion. The present dose of atropine was chosen,
foot was arrested by inflating a cuff around the ankle because we had previously found that it abolished the
during blood flow determinations, which were performed vasodilator response to intra-arterial acetylcholine infusion
at 15-s intervals over a 5-min period [18]. [20].
2.4. Measurement of cardiac output 2.6.3. Protocol 3: cardiovascular effects of an
equipressive dose of phenylephrine infusion performed
Cardiac output was measured using echocardiography alone and during cholinergic blockade
[19]. The cross sectional area of the left ventricular outflow The aim of this protocol was to test whether the
tract was multiplied by the velocity time integral of the potentiation of the vasoconstriction by cholinergic block-
systolic flow to obtain the stroke volume. The cardiac ade was specific for the NO-dependent vasoconstrictor
output was then calculated by multiplying the stroke L-NMMA or not. To this end we examined the effects of
volume by the HR. The diameter of the left ventricular cholinergic blockade on the vasoconstrictor response
outflow tract was determined in a parasternal long axis evoked by the non-NO-dependent vasoconstrictor
view and the systolic flow by a pulse Doppler sample from phenylephrine. Five of the subjects returned for this
an apical 5 chamber view. protocol. The timing of the phenylephrine infusions was
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identical to that of the L-NMMA infusions in protocols 1
and 2. In a first session, after 30 min of normal saline
infusion (1 ml /min), they received a 15-min phenylephrine
infusion titrated at a dose to match the increase in arterial
pressure observed during the L-NMMA infusion. Hemo-
dynamic measurements were recorded during two 5-min
periods of the saline infusion and during the last 5 min of
the phenylephrine infusion.
In a second session, on a separate day, the same dose of
phenylephrine was superimposed on an atropine infusion at
the same dose as that used in protocol 2. Hemodynamic
measurements were recorded during two 5-min periods of
baseline and atropine infusion, and during the last 5 min of
the phenylephrine–atropine infusion.
2.6.4. Protocol 4: hemodynamic effects of L-NMMA and
atropine during concomitant propranolol infusion
Since we found that in protocol 2 HR increased during
the L-NMMA infusion, the aim of this protocol was to test
whether this effect was caused by b-adrenergic stimula-
tion. Four of the subjects returned for this study. The
protocol was identical to protocol 2, except that together
with atropine, propranolol was co-infused as a prime (0.1
mg/kg over 10 min) continuous (0.01 mg/kg/min) infu-
sion. This dose of propranolol abolishes isoproteronol-
induced hemodynamic and chronotropic responses [20].
Fig. 1. Mean (6S.E.) effects in the same five normal subjects, of2.7. Data analysis
L-NMMA or phenylephrine infusion performed alone (open circles), and
performed during concomitant atropine infusion (closed circles) on mean
Mean arterial pressure was calculated as diastolic pres- arterial pressure and calf vascular resistance. Cholinergic blockade
sure plus one third pulse pressure. Vascular resistance in potentiated the pressor and vasoconstrictor responses to infusion of the
NO-dependent vasoconstrictor L-NMMA (*, P,0.05 vs. L-NMMAthe calf was calculated as mean arterial pressure in
alone), but did not alter the responses to the non-NO-dependent vasocon-millimeters of mercury divided by blood flow in milliliters
strictor phenylephrine (P,0.05, for the comparisons between L-NMMA–per min per 100 milliliters of tissue and expressed in units.
atropine and both phenylephrine–atropine and phenylephrine alone).
Systemic vascular resistance was calculated as mean
arterial pressure divided by the cardiac output and ex-
5pressed in dynes s per cm . The measurements of calf
blood flow, arterial pressure and HR that were collected
arterial pressure was roughly three times larger in theover 5-min periods were averaged to a single value.
presence than in the absence of cholinergic blockadeStatistical analysis was performed with paired two-tailed (38617 vs. 1366 mmHg, P50.002). Similarly, the in-t-tests and the Wilcoxon signed-rank test, as appropriate. A 5
crease in systemic (437644 vs. 303623 dynes s /cm ,P value of ,0.05 was considered to indicate statistical
P50.039) and calf vascular resistance (18611 vs. 864significance. Unless stated otherwise data are expressed as
units, P50.02) was significantly larger during L-NMMA–mean6S.D.
atropine infusion than during L-NMMA infusion alone.
Cholinergic blockade also altered the HR response to NOS
inhibition. During L-NMMA alone, the HR decreased by
3. Results 1065 beats /min, whereas when L-NMMA was adminis-
tered during atropine infusion, the HR increased by 14612
3.1. Effects of cholinergic blockade on the beats /min (P50.004 for the comparison between L-
cardiovascular responses to L-NMMA infusion NMMA alone and L-NMMA–atropine). The L-NMMA-
induced hemodynamic effects plateaued after the 10th
Cholinergic blockade markedly potentiated the L- minute of infusion (data not shown) and were related to
NMMA induced pressor and vasoconstrictor effects (Fig. NO inhibition, because they were reversed by L-arginine
1, Table 1). The L-NMMA-induced increase in mean (but not D-arginine, data not shown) infusion (Table 1).
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Table 1
aResponses to L-NMMA infusions given alone or during concomitant atropine infusion
bVariable Baseline L-NMMA L-Arginine Baseline Atropine L-NMMA 1 L-Arginine 1 P value
infusion infusion infusion atropine atropine
infusion infusion
Heart rate 6266 5264 6167 6768 92610 106618 94611 0.004
(beats /min)
Mean arterial pressure 80611 9369 8169 81611 91613 129626 95610 0.002
(mmHg)
Calf blood flow 1.660.6 1.660.7 1.760.8 1.860.6 2.060.9 2.060.8 1.960.8 NS
(ml /min /100 ml)
Calf vascular resistance 51614 60617 48611 4666 4669 64618 50612 0.02
(units)
a Values are mean6S.D. for eight subjects.
b P values are for the comparisons of the L-NMMA-induced changes from baseline, respectively from atropine infusion alone.
3.2. Effects of cholinergic blockade on the 0.03, for the comparison between L-NMMA–atropine and
cardiovascular responses to an equipressive L-NMMA–atropine–propranolol).
phenylephrine infusion
Fig. 1 shows that atropine infusion did not alter the 4. Discussion
pressor and calf vasoconstrictor responses to phenylephrine
infusion. Mean arterial pressure increased by 962 mmHg Cholinergic vasodilation has been thought to play little,
(P50.001) during phenylephrine alone and by 962 mmHg if any, role in the regulation of blood pressure in humans
(P50.002) during phenylephrine–atropine infusion. At- [16,21]. We found that cholinergic blockade had a dramatic
ropine prevented the phenylephrine-induced decrease in effect on the pressor response to NOS inhibition in these
HR; HR decreased during phenylephrine alone, whereas it healthy subjects, since the L-NMMA-induced increase in
remained unchanged during phenylephrine–atropine infu- mean arterial pressure was roughly three times larger in the
sion (Table 2). presence than in the absence of atropine infusion. Our data
indicate that cholinergic vasodilation is much more im-
3.3. Effects of propranolol on HR responses to portant than previously thought, and offsets roughly two
concomitant L-NMMA–atropine infusion thirds of the pressor effect caused by NOS inhibition. The
potentiation of the pressor effect by cholinergic blockade
Propranolol did not alter the pressor response to L- was specific for NO-dependent vasoconstriction (as evi-
NMMA–atropine infusion (mean arterial pressure in- denced by the phenylephrine studies). Moreover, the L-
creased by 2969 and 32614 mmHg in the presence and NMMA-induced hemodynamic effects were related spe-
absence of propranolol, respectively), but abolished the cifically to inhibition of NO synthesis, since they were
L-NMMA-induced increase HR; when L-NMMA was reversed by L-arginine (but not D-arginine) infusion. Auto-
infused during atropine alone, it increased the HR from nomic denervation potentiates the vasoconstrictor effect of
9365 to 10369 beats /min (P,0.05), whereas when it was NOS inhibition in humans, but it is not clear whether this
infused during atropine–propranolol, HR remained un- observation is related to augmented contribution of NO to
changed at 8365 and 8266 beats /min, respectively (P5 local vascular resistance regulation after denervation or to
Table 2
aResponses to phenylephrine infusions given alone or during concomitant atropine infusion
bVariable Baseline Phenylephrine Baseline Atropine Phenylephrine1 P value
infusion infusion atropine
infusion
Heart rate 6669 5664 6968 93614 94616 0.03
(beats /min)
Mean arterial pressure 8365 9265 81611 8968 98610 NS
(mmHg)
Calf blood flow 1.560.9 1.460.8 1.660.8 1.860.8 1.860.8 NS
(ml /min /100 ml)
Calf vascular resistance 58615 64618 52612 50612 55613 NS
(units)
a Values are mean6S.D. for five subjects.
b P values are for the comparisons of the phenylephrine-induced changes from baseline, respectively from atropine infusion alone.
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loss of neuronal non-nitric-oxide-dependent vasodilator We are indebted to Dr. Reza Owlya for performing the
echocardiographic measurements.mechanisms [17]. The present findings could be consistent
with the hypothesis that this augmented vasoconstriction
was related, at least in part, to the latter mechanism.
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